Targeting childhood, adolescent and young adult non-Hodgkin lymphoma

Therapeutic horizons

Paul J. Galardy, Tibor Bedekovics, Michelle L. Hermiston

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Non-Hodgkin lymphoma (NHL) is the third most common malignancy in children, adolescents and young adults (CAYA). NHL is a diverse set of diseases that arise at key regulatory checkpoints during B or T cell development in the bone marrow, germinal centre or thymus. While advances in the use of conventional cytotoxic agents have led to dramatic improvements in survival, these cures are associated with significant acute and long-term toxicities. Moreover, the prognosis for CAYA patients with relapsed or refractory NHL remains dismal, with the vast majority dying of their disease. Thanks to a large number of candidate-based biological studies, together with large-scale sequencing efforts, there has been an explosion of knowledge regarding the molecular pathophysiology of B- and T-NHL. This has ushered development of a flurry of novel therapeutic approaches that may simultaneously provide new hope for relapsed patients and an opportunity to reduce the therapeutic burden in newly diagnosed CAYA. Here we review a selection of the most promising new therapeutic approaches to these diseases. While the vast majority of these agents are untested in children, on-going work from many cooperative groups will soon explore their use in paediatric disease, in hope of further improving outcomes while maximizing quality of life.

Original languageEnglish (US)
Pages (from-to)625-636
Number of pages12
JournalBritish Journal of Haematology
Volume173
Issue number4
DOIs
StatePublished - May 1 2016

Fingerprint

Hodgkin Disease
Non-Hodgkin's Lymphoma
Young Adult
Germinal Center
Explosions
Cytotoxins
Therapeutics
Thymus Gland
B-Lymphocytes
Bone Marrow
Quality of Life
Pediatrics
T-Lymphocytes
Survival
Neoplasms

Keywords

  • Adolescent
  • Childhood
  • Non-Hodgkin lymphoma
  • Young adult

ASJC Scopus subject areas

  • Hematology

Cite this

Targeting childhood, adolescent and young adult non-Hodgkin lymphoma : Therapeutic horizons. / Galardy, Paul J.; Bedekovics, Tibor; Hermiston, Michelle L.

In: British Journal of Haematology, Vol. 173, No. 4, 01.05.2016, p. 625-636.

Research output: Contribution to journalArticle

Galardy, Paul J. ; Bedekovics, Tibor ; Hermiston, Michelle L. / Targeting childhood, adolescent and young adult non-Hodgkin lymphoma : Therapeutic horizons. In: British Journal of Haematology. 2016 ; Vol. 173, No. 4. pp. 625-636.
@article{0578dae49cd4441a8f30e97d43e6bbd9,
title = "Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: Therapeutic horizons",
abstract = "Non-Hodgkin lymphoma (NHL) is the third most common malignancy in children, adolescents and young adults (CAYA). NHL is a diverse set of diseases that arise at key regulatory checkpoints during B or T cell development in the bone marrow, germinal centre or thymus. While advances in the use of conventional cytotoxic agents have led to dramatic improvements in survival, these cures are associated with significant acute and long-term toxicities. Moreover, the prognosis for CAYA patients with relapsed or refractory NHL remains dismal, with the vast majority dying of their disease. Thanks to a large number of candidate-based biological studies, together with large-scale sequencing efforts, there has been an explosion of knowledge regarding the molecular pathophysiology of B- and T-NHL. This has ushered development of a flurry of novel therapeutic approaches that may simultaneously provide new hope for relapsed patients and an opportunity to reduce the therapeutic burden in newly diagnosed CAYA. Here we review a selection of the most promising new therapeutic approaches to these diseases. While the vast majority of these agents are untested in children, on-going work from many cooperative groups will soon explore their use in paediatric disease, in hope of further improving outcomes while maximizing quality of life.",
keywords = "Adolescent, Childhood, Non-Hodgkin lymphoma, Young adult",
author = "Galardy, {Paul J.} and Tibor Bedekovics and Hermiston, {Michelle L.}",
year = "2016",
month = "5",
day = "1",
doi = "10.1111/bjh.14016",
language = "English (US)",
volume = "173",
pages = "625--636",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Targeting childhood, adolescent and young adult non-Hodgkin lymphoma

T2 - Therapeutic horizons

AU - Galardy, Paul J.

AU - Bedekovics, Tibor

AU - Hermiston, Michelle L.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Non-Hodgkin lymphoma (NHL) is the third most common malignancy in children, adolescents and young adults (CAYA). NHL is a diverse set of diseases that arise at key regulatory checkpoints during B or T cell development in the bone marrow, germinal centre or thymus. While advances in the use of conventional cytotoxic agents have led to dramatic improvements in survival, these cures are associated with significant acute and long-term toxicities. Moreover, the prognosis for CAYA patients with relapsed or refractory NHL remains dismal, with the vast majority dying of their disease. Thanks to a large number of candidate-based biological studies, together with large-scale sequencing efforts, there has been an explosion of knowledge regarding the molecular pathophysiology of B- and T-NHL. This has ushered development of a flurry of novel therapeutic approaches that may simultaneously provide new hope for relapsed patients and an opportunity to reduce the therapeutic burden in newly diagnosed CAYA. Here we review a selection of the most promising new therapeutic approaches to these diseases. While the vast majority of these agents are untested in children, on-going work from many cooperative groups will soon explore their use in paediatric disease, in hope of further improving outcomes while maximizing quality of life.

AB - Non-Hodgkin lymphoma (NHL) is the third most common malignancy in children, adolescents and young adults (CAYA). NHL is a diverse set of diseases that arise at key regulatory checkpoints during B or T cell development in the bone marrow, germinal centre or thymus. While advances in the use of conventional cytotoxic agents have led to dramatic improvements in survival, these cures are associated with significant acute and long-term toxicities. Moreover, the prognosis for CAYA patients with relapsed or refractory NHL remains dismal, with the vast majority dying of their disease. Thanks to a large number of candidate-based biological studies, together with large-scale sequencing efforts, there has been an explosion of knowledge regarding the molecular pathophysiology of B- and T-NHL. This has ushered development of a flurry of novel therapeutic approaches that may simultaneously provide new hope for relapsed patients and an opportunity to reduce the therapeutic burden in newly diagnosed CAYA. Here we review a selection of the most promising new therapeutic approaches to these diseases. While the vast majority of these agents are untested in children, on-going work from many cooperative groups will soon explore their use in paediatric disease, in hope of further improving outcomes while maximizing quality of life.

KW - Adolescent

KW - Childhood

KW - Non-Hodgkin lymphoma

KW - Young adult

UR - http://www.scopus.com/inward/record.url?scp=84961700399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961700399&partnerID=8YFLogxK

U2 - 10.1111/bjh.14016

DO - 10.1111/bjh.14016

M3 - Article

VL - 173

SP - 625

EP - 636

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -